Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single-dose TAK-792 safety, tolerability, and PK in healthy adults
jRCT2080222845Phase 1
- Sponsor
- Takeda
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing TAK-792 with Placebo (2 arms). Primary endpoints: Safety and tolerability of a single oral dose of TAK-792 and Pharmacokinetics of TAK-792 after a single dose.
02
Drugs
Sucunamostat
Beyond the preview
Go deeper on jRCT2080222845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222845.